Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Alfresa Holdings Corporation

Market Cap 399B 2.49B 2.16B 1.99B 1.86B 3.48B 238B 3.56B 23.74B 9.19B 115B 9.34B 9.14B P/E Ratio 2026
11x
P/E Ratio 2027 * 16.9x
Enterprise Value 399B 2.49B 2.16B 1.99B 1.86B 3.48B 238B 3.56B 23.74B 9.19B 115B 9.34B 9.14B EV / Sales 2026
0.15x
EV / Sales 2027 * 0.13x
Free-Float
88.28%
Yield 2026
2.69%
Yield 2027 * 3.23%
05-18 Alfresa Holdings Corporation's Equity Buyback announced on May 15, 2026, has closed with 6,307,800 shares, representing 3.47% for ¥14,999.95 million. CI
05-18 Tranche Update on Alfresa Holdings Corporation's Equity Buyback Plan announced on May 15, 2026. CI
05-15 Alfresa Holdings Corporation authorizes a Buyback Plan. CI
05-15 Alfresa Holdings Corporation announces an Equity Buyback for 6,307,800 shares, representing 3.46% for ¥14,999.95 million. CI
05-15 Alfresa Holdings Corp - to buy back up to 3.5% of own shares worth about 15 billion yen RE
05-15 Alfresa Holdings Corporation Announces Cash Dividend for the Year-End of the Fiscal Year Ended March 31, 2026, Payable on June 2, 2026; Provides Cash Dividend Guidance for the Second Quarter-End and Year-End of the Fiscal Year Ending March 31, 2027 CI
05-15 Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and for the Fiscal Year Ending March 31, 2027 CI
04-07 Healios Secures 144 Million Yen Initial Order from Alfresa's Korean Unit for Cosmetic Raw Material MT
02-27 Alfresa Holdings Corporation concluded a share transfer agreement to acquire Techno Suzuta, Co.,Ltd. from Onsendo, K.K. CI
02-10 Alfresa Books 15.4 Billion Yen Gain from Sale Of Investment Securities MT
02-10 Alfresa Holdings Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
02-02 ARS Pharmaceuticals Announces EURneffy 1 Mg (Adrenaline Nasal Spray) Recommended For Approval In The EU For Emergency Treatment Of Type 1 Allergic Reactions In Children Weighing 15 Kg To Less Than 30 Kg CI
01-21 Healios Signs LOI with Alfresa for Ongoing Supply of Stem Cell Culture Supernatant MT
1 day-0.09%
1 week+0.09%
Current month-1.70%
1 month-6.27%
3 months-12.14%
6 months-9.51%
Current year-9.63%
1 week 2,190
Extreme 2190
2,242.5
1 month 2,106.5
Extreme 2106.5
2,409.5
Current year 2,106.5
Extreme 2106.5
2,685.5
1 year 1,923.5
Extreme 1923.5
2,685.5
3 years 1,897
Extreme 1897
2,685.5
5 years 1,505
Extreme 1505
2,685.5
10 years 1,505
Extreme 1505
3,350
Manager TitleAgeSince
Chief Executive Officer 63 -
Chief Tech/Sci/R&D Officer 63 28/06/2022
Corporate Officer/Principal 61 01/04/2020
Director TitleAgeSince
Director/Board Member 63 01/06/2007
Director/Board Member 65 25/06/2025
Director/Board Member 50 01/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.09%+0.09%+13.63%+0.55% 2.49B
+1.04%-0.57%-33.28%-10.99% 155B
+0.54%-1.38%-8.25%-4.13% 103B
+0.61%+4.69%-1.27%+57.82% 54.72B
-0.23%-6.71%+50.66%+49.87% 53.65B
-0.11%-1.42%-14.64%-41.19% 40.72B
+1.23%+6.89% - - 30.9B
+1.00%+4.23%-8.83%-40.38% 28.85B
+0.39%+4.56%+48.11%-7.16% 23.38B
-1.93%-0.66%-14.31%+2.17% 21.22B
Average +0.23%+2.35%+3.54%+0.73% 51.43B
Weighted average by Cap. +0.51%+2.28%-6.96%+1.54%

Financials

2026 2027 *
Net sales 3,099B 19.31B 16.76B 15.45B 14.47B 27.04B 1,849B 27.6B 184B 71.33B 891B 72.48B 70.92B 3,164B 19.72B 17.11B 15.77B 14.78B 27.61B 1,888B 28.19B 188B 72.85B 910B 74.02B 72.43B
Net income 37.04B 231M 200M 185M 173M 323M 22.1B 330M 2.2B 853M 10.65B 866M 848M 25.25B 157M 137M 126M 118M 220M 15.06B 225M 1.5B 581M 7.26B 591M 578M
Net Debt - -
Logo Alfresa Holdings Corporation
Alfresa Holdings Corporation is a Japan-based holding company primarily engaged in the wholesale of drugs. The Company operates in four business segments. The Pharmaceutical Wholesale segment is engaged in the wholesale of medical products, test reagents, as well as medical equipment and materials. The Self Medication Wholesale segment is engaged in the wholesale of general drugs. The Pharmaceutical Manufacture segment is engaged in the manufacture and sale of pharmaceuticals, test reagents, medical equipment and implements, as well as pharmaceutical powders. The Medical-Related segment is mainly engaged in operation of pharmacies. The others business is engaged in the information system business, the transportation business, the warehousing business, the insurance agency business, the real estate management business, the sale of miscellaneous goods, as well as the manpower dispatching business, among others.
Employees
12,452
Date Price Change Volume
11/06/26 2,197.00 ¥ -0.09% 520,700
10/06/26 2,199.00 ¥ -0.50% 619,200
09/06/26 2,210.00 ¥ 0.00% 358,800
08/06/26 2,210.00 ¥ +0.45% 443,500
05/06/26 2,200.00 ¥ 0.00% 409,100
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
2,197.00JPY
Average target price
2,500.00JPY
Spread / Average Target
+13.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2784 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!